Quick Answer
ZyVersa Therapeutics, Inc. reported Operating Income Loss of -$25.49 million for the year ending 2025.
- ZyVersa Therapeutics, Inc. showed a decrease of -179.0% in Operating Income Loss from 2024 to 2025.
- This data is from ZyVersa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2022 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2022 to 2025), ZyVersa Therapeutics, Inc.'s Operating Income Loss has declined by 95.9%.
- Historical annual values: Fiscal year 2025: -$25.49 million | Fiscal year 2024: -$9.14 million | Fiscal year 2023: -$107.75 million | Fiscal year 2022: -$820.1 thousand | Fiscal year 2022: -$13.01 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: